Report Highlights

Italy Gastritis Treatment: Market Overview

The Italian gastritis treatment market is shaped by a dual burden: a structurally high H. pylori infection prevalence significantly above the Western European average, and an ageing population with elevated NSAID use driving autoimmune and chemical gastritis diagnoses. Italy's National Health Service, the Servizio Sanitario Nazionale (SSN), governs reimbursement tightly through the Agenzia Italiana del Farmaco (AIFA), making formulary access the decisive commercial variable. Branded originator products compete intensively against a well-established generic infrastructure, with hospital and community pharmacy channels operating under distinct pricing dynamics that require separate commercial strategies.

Unlike Germany or France where specialist-driven prescribing dominates, Italy's gastritis treatment landscape is substantially driven by general practitioners operating within regional health authorities known as Aziende Sanitarie Locali (ASLs). This decentralised structure creates meaningful geographic fragmentation: per-capita spending on gastritis therapeutics in northern Italy's Lombardy region exceeds that of Calabria by approximately 2.3 times, reflecting income disparities, healthcare infrastructure gaps, and differential ASL formulary inclusions. The market recorded USD 1.04 billion in 2024 and is projected to reach USD 1.61 billion by 2032, representing one of the more resilient Southern European pharmaceutical sub-markets.

Growth Drivers in the Italy Gastritis Treatment Market

Three country-specific demand drivers sustain above-average growth. First, Italy's population aged over 65 now constitutes 23.8% of the total — the second-highest share in the European Union — and this cohort carries disproportionately high NSAID prescription rates for osteoarthritis and cardiovascular comorbidities, directly elevating chemical and erosive gastritis incidence. The Italian Ministry of Health's Piano Nazionale della Cronicità, updated in 2022, explicitly identifies chronic gastrointestinal disease management as a priority, allocating co-financing to regional ASLs for diagnostic expansion, including non-invasive H. pylori breath test reimbursement that increases diagnosis rates and consequently treatment volumes.

Second, the Italian government's 2023 nutritional surveillance data confirmed that Mediterranean diet adherence among urban youth under 35 has declined markedly, correlating with increased alcohol consumption, processed food intake, and stress-related acute gastritis presentations in emergency departments in Milan, Rome, and Naples. Third, Italy's ongoing implementation of the PNRR (Piano Nazionale di Ripresa e Resilienza) healthcare investment pillar, backed by EUR 7 billion directed at community health infrastructure, is accelerating gastroenterology outpatient capacity in underserved southern regions, directly expanding the diagnosable and treatable patient pool for the first time in a decade.

Market Restraints and Entry Barriers

The principal structural barrier for new entrants is AIFA's pharmaceutical classification and reimbursement system. Products must obtain either a Class A designation — fully reimbursed by SSN — or Class H status for hospital-only reimbursement. The process routinely takes 18 to 36 months from European Medicines Agency approval to Italian market access, and AIFA's Cost-Effectiveness and Budget Impact dossier requirements are among the most stringent in the EU. For gastritis treatments, where established generics define the therapeutic baseline, demonstrating incremental clinical benefit sufficient to justify a Class A branded premium is commercially difficult without robust Italian-specific clinical data.

Distribution complexity adds a further layer of operational challenge. Italian pharmaceutical wholesale is concentrated among three major distributors — Comifar, Alliance Healthcare Italia, and OCP Italia — who negotiate margin structures that compress net realisation for mid-sized foreign entrants lacking scale. Pharmacy-level generic substitution, mandated under Law 405/2001 and reinforced by subsequent AIFA guidance, means that even successfully registered branded gastritis products face automatic pharmacy substitution unless physicians explicitly annotate prescriptions as non-substitutable. Regional formulary fragmentation across Italy's 20 regions requires separate stakeholder engagement with each ASL's Commissione Terapeutica, multiplying market access costs substantially.

Market Opportunities in Italy

The most immediately actionable opportunity lies in next-generation H. pylori eradication regimens. Standard clarithromycin-based triple therapy is now exhibiting eradication failure rates above 25% in Italian clinical settings due to documented clarithromycin resistance, and Italian gastroenterology guidelines — updated by the Associazione Italiana Gastroenterologi ed Endoscopisti Ospedalieri (AIGO) in 2023 — formally recommend bismuth-based quadruple therapy as first-line in high-resistance regions. Entrants with licensed bismuth quadruple kits or rifabutin-based rescue regimens face a genuine clinical unmet need, with the addressable resistant-H. pylori patient segment estimated at 280,000 to 320,000 treatment courses annually.

A secondary opportunity exists in the mucosal protective and cytoprotective agent segment, specifically sucralfate and rebamipide formulations, which Italian gastroenterologists are increasingly prescribing as adjuncts to PPI therapy in NSAID-dependent elderly patients. This adjunct use is not yet standardised in SSN guidelines, creating a window for companies able to generate Italian pharmacoeconomic evidence demonstrating hospitalisation avoidance value. The digital therapeutics and remote monitoring adjacency is also opening, as the PNRR's Missione 6 investment is creating telemedicine infrastructure that enables GPs to manage chronic gastritis patients digitally, expanding adherence monitoring product opportunities for pharmaceutical companies with digital companion tools.

Market at a Glance

Leading Market Participants

• AstraZeneca Italy
• Takeda Italia
• Pfizer Italia
• Menarini Group
• Recordati S.p.A.
• Almirall Italy
• Italfarmaco S.p.A.
• Sandoz Italy (Novartis Generics)
• EG S.p.A. (Stada Group)
• Teva Italia S.r.l.

Regulatory and Policy Environment

The regulatory framework governing gastritis treatments in Italy is administered by AIFA under the authority of Legislative Decree 219/2006, which transposed EU Directive 2001/83/EC into Italian law. All pharmaceutical products require AIFA price negotiation before SSN reimbursement, conducted through the Comitato Prezzi e Rimborso (CPR). For generic gastritis drugs — including pantoprazole, omeprazole, lansoprazole, and amoxicillin-clarithromycin combinations — AIFA maintains a reference pricing system that is revised quarterly, ensuring continuous downward pricing pressure. The Law 648/1996 pathway provides a mechanism for off-label or non-yet-approved treatments to be reimbursed in cases of proven therapeutic need, occasionally relevant for novel H. pylori rescue regimens pending full approval.

From a compliance and market access standpoint, pharmaceutical companies operating in Italy must adhere to the Farmindustria Code of Ethics and AIFA's strict transparency rules on healthcare professional interactions, updated under the 2023 revision of Legislative Decree 24/2023 implementing the EU Falsified Medicines Directive. Pharmacovigilance reporting obligations require dedicated local qualified persons. Italy's participation in the EU Joint Clinical Assessment framework under HTA Regulation 2021/2282, which begins mandatory application for oncology and ATMP products from 2025 and expands to other therapeutic areas by 2030, will progressively affect how gastritis treatment clinical evidence dossiers are constructed for AIFA submission, favouring companies that invest early in Italian real-world evidence generation.

Long-Term Outlook for Italy Gastritis Treatment

By 2032, the Italian gastritis treatment market will be structurally bifurcated between a high-volume, low-margin generic PPI and antibiotic segment and a smaller but faster-growing premium segment comprising resistance-targeted eradication therapies, biologic-adjacent mucosal agents, and microbiome-modulating adjuncts. Consolidation among Italian generic manufacturers — already visible in Recordati's acquisition strategy and EG S.p.A.'s portfolio expansion — will further compress margins in the commodity segment, while SSN budget pressures incentivise AIFA to enforce reference pricing more aggressively, leaving limited room for incremental branded PPI growth.

The most significant long-term value will accrue to companies that establish clinical and commercial depth in H. pylori antimicrobial resistance management and in gastroprotection for the growing elderly polypharmacy population. Italy's demographic trajectory — the UN projects Italy's median age will reach 51.4 years by 2032 — structurally guarantees demand growth independent of dietary or lifestyle improvements. Companies that secure Class A reimbursement for differentiated formulations before 2028 and build trusted relationships with Italy's 7,600 registered gastroenterologists will hold durable competitive positions that are difficult for later entrants to displace given AIFA's deliberate and slow formulary revision cycles.